Previous Close | 0.0250 |
Open | 0.0000 |
Bid | 0.0300 x 0 |
Ask | 0.0350 x 0 |
Day's Range | 0.0250 - 0.0250 |
52 Week Range | 0.0250 - 0.1400 |
Volume | |
Avg. Volume | 26,817 |
Market Cap | 1.158M |
Beta (5Y Monthly) | 2.70 |
PE Ratio (TTM) | 0.16 |
EPS (TTM) | 0.1540 |
Earnings Date | Aug 21, 2020 - Aug 25, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.01 |
Toronto, Ontario--(Newsfile Corp. - March 7, 2023) - BELGRAVIA HARTFORD CAPITAL INC. (CSE: BLGV) ("Belgravia Hartford", "Belgravia" or the "Company") is pleased to announce that on December 7, 2022, the Ontario Superior Court of Justice entered a Default Judgment against R&D Pharma Corp. ("R&D Pharma") in the case entitled Belgravia Capital International Inc. v. R&D Pharma Corp. (the "Parties"). Belgravia received the Judgment on February 1, 2023. The defendant, R&D Pharma, is ordered to ...
Toronto, Ontario--(Newsfile Corp. - January 13, 2023) - BELGRAVIA HARTFORD CAPITAL INC. (CSE: BLGV) ("Belgravia Hartford", "Belgravia" or the "Company") provides an update on the debt owed by Zonetail Inc. (TSXV: ZONE) ("Zonetail") and its litigation with Zonetail. Zonetail Debt Payment of the debt owed to Belgravia by Zonetail under the promissory note (the "Debt") in the current amount of approx. $506,125 including interest at 18%, continues to remain outstanding. Zonetail paid an interest pay
Toronto, Ontario--(Newsfile Corp. - January 12, 2023) - BELGRAVIA HARTFORD CAPITAL INC. (CSE: BLGV) ("Belgravia Hartford", "Belgravia" or the "Company") is pleased to provide a corporate update on the Company.Normal Course Issuer Bid ("NCIB")The Company also announces has purchased through its NCIB for cancellation, a total of 100,000 common shares ("Common Shares") at an average price of $0.04 per share. As of December 31, 2022, the Company has purchased for cancellation approximately 35.98% of